Tier 4 — mechanistic
REVITALiSE: Randomised Evaluation Platform — Interventions to Treat Older People With Sarcopenia
ISRCTN trial registry record
2025
Bibliography
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Funded by the NIHR Newcastle Biomedical Research Centre; sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust.
- Competing interests
- No manuscript-level competing-interest statement is available for this registry protocol.
Study snapshot
| Design | Single-centre open-label platform trial with independently randomized parallel subtrials; the initial subtrial compares fisetin with usual care. |
|---|---|
| Model | Adults aged 65 years and older with low grip strength or impaired sit-to-stand performance consistent with sarcopenia. |
| Sample | Approximately 36 participants planned for the fisetin subtrial; the platform protocol states roughly 30-40 per subtrial. |
| Intervention | Fisetin 400 mg capsules once daily for three consecutive days every two weeks for 12 weeks. Weight-based daily dose: 800 mg at ≤50 kg, 1,200 mg at 50-69.9 kg, 1,600 mg at 70-89.9 kg, and 2,000 mg at ≥90 kg. Comparator: usual care. |
| Duration | 12 weeks. |
| Endpoints | Primary: 4-metre walk speed; Grip strength; Physical activity and digital mobility outcomes; Short Physical Performance Battery; Adherence; Adverse events; Muscle biopsy and mechanistic outcomes |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Fisetin Senolytic: Does It Clear Senescent Cells in Humans?Fisetin is clearly senolytic in some experimental cell systems and strongly senotherapeutic in animals, but controlled proof of systemic senescent-cell clearance in...Read analysis
- Fisetin Benefits: What the Evidence Actually ShowsFisetin has strong preclinical evidence as a senotherapeutic, but human findings remain early and mixed. This evidence review separates randomized trials, human...Read analysis
- Fisetin Dosage: What Human Studies Actually UseThere is no single established fisetin dose. Human studies have used 100 mg/day, 200–800 mg/day, 2 mg/kg intermittent dosing, ~20 mg/kg senolytic...Read analysis
- Fisetin Pulse Dosing: What Human Trials Actually UseThere is no single Mayo Clinic fisetin protocol. Human trials use one-, two- and three-day pulses, with repeat intervals ranging from one...Read analysis
- Best Fisetin Supplement (2026): The Complete Buyer's GuideCompare ten fisetin supplements on ingredient transparency, batch testing, formulation and dose format, with US/UK/Canada purchasing considerations. DoNotAge Pure Fisetin is our...Read analysis
- Fisetin for Muscle Preservation and Frailty: The Evidence (2026)A 2025 mouse study linked intermittent fisetin with better physical function and lower skeletal-muscle senescence markers in aged mice. Human studies are...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
